SPXE:ARCA-ProShares S&P 500 Ex-Energy

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 62.24

Change

+0.46 (+0.75)%

Market Cap

USD 9.07M

Volume

100.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks investment results, before fees and expenses that track the performance of the S&P 500? Ex-Energy Index (the "index"). Under normal circumstances, the fund will invest at least 80% of its total assets in component securities. The index seeks to provide exposure to the companies of the S&P 500? Index (the "S&P 500?") with the exception of those companies included in the Energy Sector.

Inception Date: 22/09/2015

Primary Benchmark: S&P 500® Ex-Energy USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.27%

Management Expense Ratio: 0.27 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-08-21 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

+0.15 (+0.29%)

N/A

ETFs Containing SPXE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.43% 58% F 74% C
Dividend Return 0.91% 74% C 25% F
Total Return 19.34% 58% F 71% C-
Trailing 12 Months  
Capital Gain 4.15% 71% C- 71% C-
Dividend Return 1.56% 65% D 30% F
Total Return 5.71% 71% C- 69% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 9.21% 74% C 79% B-
Dividend Return 10.49% 76% C+ 76% C+
Total Return 1.28% 79% B- 28% F
Risk Return Profile  
Volatility (Standard Deviation) 8.91% 82% B 76% C+
Risk Adjusted Return 117.65% 97% N/A 93% A
Market Capitalization 9.07M 26% F 23% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.